News
LabPMM™ is the only reference laboratory outside Japan licensed to perform comprehensive FLT3 mutation testing. Assessment of FLT3 mutation status in karyotype normal AML is the most important prognostic indicator of disease outcome, which is often substantial, as many studies in AML have shown that the presence of FLT3 mutations portends a poor prognosis. For this reason FLT3 mutation testing is required to stratify disease and determine appropriate treatment options.
Please contact us directly for specific information prior to sending specimens.
Update - December 2008
LabPMM™ is pleased to announce that we have obtained a license to perform NPM1 mutation testing. The license includes the ability to monitor patients using ultra-sensitive minimal residual disease (MRD) tests.
Presence of NPM1 mutations in patients with karyotype normal acute myeloid leukemia (AML) portends a more favorable prognosis than patients that lack NPM1 mutations. While presence of FLT3 activating mutation alone portends a very poor prognosis for patients with AML, when the FLT3 mutation is present with an NPM1 mutation, the overall prognosis for the patient is somewhat more favorable. Accordingly, NPM1 mutation testing complements our exclusive license to test for FLT3 activating mutations.
Assessment of FLT3 and NPM1 mutation status has become an internationally recognized Standard of Care for patients with acute myeloid leukemia. Testing the mutation status of both of these biomarkers is necessary for disease stratification and optimal treatment selection for patients with AML.
LabPMM™ is the sole reference laboratory in the US licensed to provide a comprehensive molecular assessment of FLT3 and NPM1 mutation status.
